Material and methods
Introduction
designed two-step-thin 27-gauge needle was used to inoculate the virus intracerebrally.
The virus was injected in the rats (13 days of age) at the midpoint between the two ears.
Adult rats, 12 weeks after the inoculation of virus, were used for further study. However control group of rat receives only diluents.
Thereafter JEV infected rats were further separated into four groups: negative control, corilagin (20 mg/kg, ip), levodopa with dopa decarboxylase inhibitor (10 mg/kg, ip) and corilagin+levodopa with dopa decarboxylase inhibitor for the duration of seven days.
Estimation of motor function
Bradykinesia was evaluated by estimating the motor activity through a pole test in rats. A pole test was done as per a previously reported study. In the pole test, the time taken by the rats of both control and JEV infected groups to fall down from the rough surfaced pole to the floor was estimated before and after the drug treatment.
Estimation of neurochemical levels
All the animals were sacrificed at the end of the protocol (i.e. immediately after the last dose of corilagin) and the brain was isolated from each animal. The isolated brain of each rat was dissected in to several parts as per a previously reported study. Each part of the brain was stored at -80 o C in liquid nitrogen.
Ethylenediaminetetraacetic acid (0.7 mM) and perchloric acid (0.1 M) was used to homogenizethe frozen brain tissues. High performance liquid chromatography (HPLC) was used to separate the catecholamines after purifying it with aluminum oxide. An electrochemical detector was used in the HPLC for the estimation of the catecholamine levels.
We attached an ECD to the HPLC apparatus to make a system based on the principle of amperometry. Protein levels were determined as per a previously reported method, using bovine serum albumin as the standard.
Statistical Analysis
Statistical analysis and results are reported 
Effect of corilagin on the level of monoamines
The effect of corilagin on the concentration of dopamine in various part of the brain such as cerebral cortex, midbrain and hypothalamus isshown in Table 2 . There was a significant decrease in the levels of dopamine in the hypothalamus and cerebral cortex of rat brainscompared to thenegative control group.
However levels of dopamine was found to be attenuatedin corilagin, LEV and LEV+corilagin treated groups.
In addition, the effect of corilagin on the concentration of dopamine in the brain striatum is shown in Fig. 2 . It was observed that treatment with corilagin and LEV alone and in combination significantly enhances the level of dopamine in the substantia nigra compared to thenegative control group. These result 
Conclusion
This study concludes that corilagin ameliorates the Parkinsonismin JEV induced Parkinsonism.
Moreover corilaginshows a synergistic effect when treated with LEV. The data presented in the investigation supports that corilagin can be used clinically. 
